How many drugs treat Increased Urinary Frequency?

Drug Landscape tracks 9 marketed treatments for Increased Urinary Frequency (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/increased-urinary-frequency.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Increased Urinary Frequency — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Increased Urinary Frequency (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Increased Urinary Frequency, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Toviaz	Fesoterodine Fumarate	Pfizer	fesoterodine	Muscarinic acetylcholine receptor M2	2008-01-01
Toviaz	FESOTERODINE	Pfizer	fesoterodine	Muscarinic acetylcholine receptor M2	2008-01-01
Vesicare	SOLIFENACIN	Astellas Pharma	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M1	2004-01-01
Sanctura	TROSPIUM	AbbVie	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M3	2004-01-01
Enablex	DARIFENACIN	AbbVie	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M3	2004-01-01
Detrol	TOLTERODINE	Upjohn	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M1	1998-01-01
Ditropan Xl	OXYBUTYNIN	Hisamitsu Pharmaceutical Co., Inc.	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M3	1975-01-01
Oxytrol	Oxytrol	Jewish General Hospital		Cytochrome P450 2C19, 5-hydroxytryptamine receptor 2B, D(3) dopamine receptor
Vesicare	Vesicare	University of California, Irvine		Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Increased Urinary Frequency
AbbVie · 2 drugs in Increased Urinary Frequency
· 2 drugs in Increased Urinary Frequency
Jewish General Hospital · 1 drug in Increased Urinary Frequency
University of California, Irvine · 1 drug in Increased Urinary Frequency
Upjohn · 1 drug in Increased Urinary Frequency
Astellas Pharma · 1 drug in Increased Urinary Frequency
Hisamitsu Pharmaceutical Co., Inc. · 1 drug in Increased Urinary Frequency

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Increased Urinary Frequency:

Cite this brief

Drug Landscape (2026). Increased Urinary Frequency — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/increased-urinary-frequency. Accessed 2026-06-10.

Increased Urinary Frequency full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing